Page 15 - Benefit Managers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

“Full Financial Risk” A. Overview of Key Safe Harbors and Exceptions An important initial consideration is that there are multiple differing requirements between corresponding Stark Law exceptions and AKS safe harbors. Stakeholders must navigate the requirements under both regulatory regimes for arrangements that potentially implicate each law. Although a number of commenters sought a unified set of requirements between Stark Law and AKS requirements, CMS and OIG rejected this approach, noting the different purposes of each law. In general, CMS provides more flexibility for Stark Law exce...

Tuesday, February 2, 2021 On 2 December 2020, the U.S. Department of Health and Human Services’ (HHS) issued two Final Rules in conjunction with its “Regulatory Sprint to Coordinated Care,” which will markedly change the regulatory fraud and abuse landscape for “value-based” arrangements: (i) The HHS Office of the Inspector General (OIG) published a Final Rule that introduces new safe harbor protections under the federal Anti-Kickback Statute (AKS) for certain coordinated care and risk-sharing value-based arrangements between or among clinicians, providers, suppliers, and...

Facing renewed scrutiny now that epstein has been charged in a new indictment alleging that he sexually abused dozens of other girls. the white house tells axios that it has called off a proposal to recall rebates from the middlemen. benefit managers negotiate reduced prices and keep some of the money for themselves. >> the white house backing away from the idea saying that it's encouraged by bipartisan talks to bring down drug prices. this is all bad news for big pharma which blames those middlemen for high drug prices. the administration is now going to focus on another idea that big pharm...

Agreement was negotiated. according to the miami herald, it was still being negotiated. it was already established. acosta's role is being questioned. a critical component of president trump's plan to force down drug prices is now dead. the white house tells axios it has called off a proposal to overhaul rebates collected by pharmacy benefit managers. those are the middlemen between insurance companies and benefit managers to negotiate discounted prices but keep some of the rebate money itself. they would have banned that arrangements for medicare and medicaid. >> the white house backing awa...

The pharmaceutical companies in a few days or weeks we are going to have the pharmacy benefit managers in. they are the ones involved mostly in the rebate issue. there is 170 billion difference between a list price and what the price the consumer pays, >> neil: i know a lot of drug companies were fingering the benefit managers that coordinate rates between insurers and employers and the drug companies -- this is what they're saying, are stuck holding the bag. did you believe them? >> no, but i'm not going to put all the blame on the pharmaceutical companies because we are going to have to have...